Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 49,700 shares, a decrease of 65.5% from the February 28th total of 143,900 shares. Based on an average daily volume of 7,100,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.3% of the company’s stock are sold short.
Biomerica Price Performance
Biomerica stock opened at $0.64 on Thursday. Biomerica has a 1-year low of $0.24 and a 1-year high of $1.27. The business has a fifty day moving average price of $0.67 and a 200-day moving average price of $0.45. The stock has a market capitalization of $11.70 million, a price-to-earnings ratio of -1.88 and a beta of -1.16.
Biomerica (NASDAQ:BMRA – Get Free Report) last issued its quarterly earnings results on Tuesday, January 14th. The company reported ($0.06) earnings per share for the quarter. Biomerica had a negative return on equity of 90.19% and a negative net margin of 100.52%.
Institutional Trading of Biomerica
About Biomerica
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Featured Articles
- Five stocks we like better than Biomerica
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Energy Transfer: Powering Data With Dividends and Diversification
- What Are Dividend Challengers?
- Qualcomm Stock Is Coiling for a Breakout
- Top Stocks Investing in 5G Technology
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.